Song‐Yang Wu

2.4k total citations · 3 hit papers
24 papers, 1.4k citations indexed

About

Song‐Yang Wu is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Song‐Yang Wu has authored 24 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Song‐Yang Wu's work include Cancer Immunotherapy and Biomarkers (8 papers), Cancer Genomics and Diagnostics (6 papers) and Advanced Breast Cancer Therapies (5 papers). Song‐Yang Wu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Cancer Genomics and Diagnostics (6 papers) and Advanced Breast Cancer Therapies (5 papers). Song‐Yang Wu collaborates with scholars based in China, United States and Singapore. Song‐Yang Wu's co-authors include Yi‐Zhou Jiang, Tong‐Ming Fu, Zhi-Ming Shao, Yi Xiao, Ding Ma, Lei-Jie Dai, Zhi-Ming Shao, Zhi‐Ming Shao, Xin Hu and Qiang Yu and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Song‐Yang Wu

23 papers receiving 1.4k citations

Hit Papers

Natural killer cells in cancer biology and therapy 2020 2026 2022 2024 2020 2021 2022 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Natural killer cells in cancer biology and therapy
    2020 578 citations Song‐Yang Wu, Tong‐Ming Fu et al. Molecular Cancer profile →
  2. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response
    2021 287 citations Tong‐Ming Fu, Lei-Jie Dai et al. Journal of Hematology & Oncology profile →
  3. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
    2022 202 citations Yi Xiao, Ding Ma et al. Cell Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Song‐Yang Wu China 14 693 597 571 382 264 24 1.4k
Chang‐Jiun Wu United States 15 700 1.0× 375 0.6× 599 1.0× 297 0.8× 221 0.8× 30 1.4k
Shelley M. Herbrich United States 14 544 0.8× 386 0.6× 602 1.1× 210 0.5× 145 0.5× 35 1.4k
Dong Yang China 19 553 0.8× 328 0.5× 503 0.9× 217 0.6× 249 0.9× 53 1.2k
Eriko Katsuta United States 24 695 1.0× 372 0.6× 773 1.4× 501 1.3× 403 1.5× 82 1.6k
Marion Thibaudin France 13 778 1.1× 630 1.1× 391 0.7× 259 0.7× 150 0.6× 25 1.4k
Gabriela Andrejeva United States 11 415 0.6× 457 0.8× 724 1.3× 520 1.4× 129 0.5× 16 1.3k
М. V. Zavyalova Russia 19 578 0.8× 226 0.4× 475 0.8× 322 0.8× 149 0.6× 76 1.1k

Countries citing papers authored by Song‐Yang Wu

Since Specialization
Citations

This map shows the geographic impact of Song‐Yang Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Song‐Yang Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Song‐Yang Wu more than expected).

Fields of papers citing papers by Song‐Yang Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Song‐Yang Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Song‐Yang Wu. The network helps show where Song‐Yang Wu may publish in the future.

Co-authorship network of co-authors of Song‐Yang Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Song‐Yang Wu. A scholar is included among the top collaborators of Song‐Yang Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Song‐Yang Wu. Song‐Yang Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Xiyu, Chao Chen, Zhiqiang Wang, et al.. (2025). MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2/MORF4L2/H4K12Ac/CSF1 axis in triple-negative breast cancer. Biomarker Research. 13(1). 6–6. 1 indexed citations
2.
Wu, Song‐Yang, et al.. (2024). Thermo-immune synergy: Camrelizumab plus microwave ablation in preoperative early-stage breast cancer. Med. 5(4). 278–280. 1 indexed citations
3.
4.
Dai, Lei-Jie, Yuwei Li, Yi Xiao, et al.. (2023). Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer. Nature Communications. 14(1). 5112–5112. 37 indexed citations
5.
Dai, Lei-Jie, Yi Xiao, Xi Jin, et al.. (2023). Abstract HER2-09: HER2-09 Multiomics Profiling Characterizes Distinct HER2-low Breast Cancer Subgroups in the East Asian Population. Cancer Research. 83(5_Supplement). HER2–9. 1 indexed citations
6.
Wu, Song‐Yang, Ding Ma, Yi Xiao, et al.. (2023). CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. Med. 4(6). 373–393.e8. 27 indexed citations
7.
Shao, Zhimin, Lei Fan, Song‐Yang Wu, et al.. (2023). FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 3011–3011. 2 indexed citations
8.
Dong, Xinran, Yulan Lu, Lanting Guo, et al.. (2023). PICOTEES: a privacy-preserving online service of phenotype exploration for genetic-diagnostic variants from Chinese children cohorts. Journal of genetics and genomics. 51(2). 243–251.
9.
Lin, Cai‐Jin, Yu‐Chen Pei, Ding Ma, et al.. (2023). Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities. Cell Discovery. 9(1). 125–125. 13 indexed citations
10.
11.
Xiao, Yi, Ding Ma, Yun‐Song Yang, et al.. (2022). Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Research. 32(5). 477–490. 202 indexed citations breakdown →
12.
Wu, Song‐Yang, Ying Xu, Li Chen, et al.. (2022). Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Molecular Cancer. 21(1). 84–84. 65 indexed citations
13.
Yu, Ke‐Da, et al.. (2021). Estrogen receptor‐low breast cancer: Biology chaos and treatment paradox. Cancer Communications. 41(10). 968–980. 37 indexed citations
14.
Shen, Minhong, Heath A. Smith, Yong Wei, et al.. (2021). Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nature Cancer. 3(1). 60–74. 45 indexed citations
15.
Fu, Tong‐Ming, Lei-Jie Dai, Song‐Yang Wu, et al.. (2021). Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. Journal of Hematology & Oncology. 14(1). 98–98. 287 indexed citations breakdown →
16.
Wu, Song‐Yang, Tong‐Ming Fu, Yi‐Zhou Jiang, & Zhi-Ming Shao. (2020). Natural killer cells in cancer biology and therapy. Molecular Cancer. 19(1). 120–120. 578 indexed citations breakdown →
17.
Wu, Song‐Yang, Hai Wang, Zhi‐Ming Shao, & Yi‐Zhou Jiang. (2020). Triple-negative breast cancer: new treatment strategies in the era of precision medicine. Science China Life Sciences. 64(3). 372–388. 32 indexed citations
18.
Wu, Song‐Yang, Hongyong He, Hao Liu, et al.. (2018). C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. OncoImmunology. 7(6). e1433517–e1433517. 16 indexed citations
19.
Wu, Song‐Yang, Hao Liu, Heng Zhang, et al.. (2016). Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery. Tumor Biology. 37(9). 12635–12642. 17 indexed citations
20.
Cao, Yifan, Heng Zhang, Hao Liu, et al.. (2016). Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer. Scientific Reports. 6(1). 38364–38364. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chang‐Jiun Wu Breakdown of academic impact, for papers by Shelley M. Herbrich Breakdown of academic impact, for papers by Dong Yang Breakdown of academic impact, for papers by Eriko Katsuta Breakdown of academic impact, for papers by Marion Thibaudin Breakdown of academic impact, for papers by Gabriela Andrejeva Breakdown of academic impact, for papers by М. V. Zavyalova
Rankless by CCL
2026